. As more biosimilars enter the US market over the coming years, they are expected to expand patient access to life-saving medications for difficult-to-treat diseases, such as cancer, anemia, and endocrine and autoimmune disorders (e.g., multiple sclerosis, rheumatoid arthritis, psoriasis, and inflammatory bowel disease) because they will offer an alternative to existing biologics for Medicare, Medicaid, and the private sector [8] .
Several of the leading biosimilar sponsors created the Biosimilars Forum in 2015 to advance biosimilars in the US with the intent of expanding access and availability of biological medicines to improve health care [9] . The Biosimilars Forum provides evidence-based information to inform and support public policies that encourage awareness, access, and adoption of biosimilars. Current members include: Allergan, Amgen, Boehringer-Ingelheim, Coherus, EMD-Serono, Merck, Pfizer, Samsung Bioepis, Sandoz, and Teva.
When generic drugs first became available in the US in the 1980s, physicians required a clear understanding of this new class of drugs before they were comfortable prescribing them to patients [10] . Similarly, it is expected that physicians will also require an in-depth understanding of biosimilars before they feel comfortable offering these new treatment options to their patients. In order to assess current levels of awareness, knowledge, and perceptions of biosimilars among specialty physicians who already prescribe biologics, the Biosimilars Forum conducted a survey through an independent organization from November 20, 2015 to January 4, 2016. The survey was intended to provide a baseline level of knowledge among specialty physicians. A similar survey will be conducted in 2-3 years time with the same design in order to monitor trends in the awareness, knowledge, and perceptions of biosimilars over time.
METHODS
A 19-question survey was created by the
Biosimilars
Forum, and a third-party organization, SERMO (a global social network organization for physicians), was contracted to conduct the survey. An attempt was made to word all questions in a neutral manner.
Respondents
were not informed that pharmaceutical companies had created the questionnaire because it was felt that knowledge of this fact might bias the responses, although it was prospectively planned to disclose this fact at the time of publication. Responses were obtained from 1201 US physicians across specialties that are high prescribers of biologics, including dermatologists, gastroenterologists, hematologist-oncologists, medical oncologists, nephrologists, and rheumatologists. The profile of SERMO US physician members closely mirrors that of all US physicians (as measured by the American Medical Association (AMA)) [11] . The anonymous respondents represented a cross-section of years of experience primarily between 6 and 30 years, although the largest portion of respondents was in practice for 11-20 years (32.8%). Survey respondents who did not prescribe biologics were excluded from the survey, and were not counted among the 1201 participants. 
RESULTS AND DISCUSSION

General Awareness of Biologics and Biosimilars
Overall, most physicians are aware of which drugs used within their specialties are biologics; however, there was a sizeable minority that did not know this information ( Fig. 1 ). Some physicians mistookchemical drugs for biologics and many selected ''none of the above,'' which indicated that they did not recognize any of the suggested therapies as biologics. These data reflect a lack of understanding of what defines a biologic, which was surprising since all physicians included in the survey responded that they prescribe biologic drugs. If physicians do not know that a given drug is a biologic, it will create an educational challenge to explain that, after patent expiry, copies of these therapies will be marketed as biosimilars instead of as generic drugs.
Although the vast majority of respondents across all specialties have heard about biosimilars ( Fig. S1 in Supplementary Materials), their actual knowledge of the fundamentals of biosimilars, as demonstrated in greater detail below, was low. For example, a sizable minority was unaware that a biosimilar was available in the US (Fig. 2 ).
Most respondents (75%) appear to trust FDA approval decisions; however, they will still want additional information when making treatment decisions ( Fig. S2 in Supplementary Materials). A small group of respondents (13%), predominantly dermatologists and rheumatologists, will not solely trust the FDA's assessments and decision to approve the biosimilar and will seek more information. Presumably, these physicians will decide which medications to use based on their own assessments. The survey did not probe further into how those decisions would be made.
Understanding and Perceptions of Key
Concepts Related to Biosimilars
Only half of respondents are knowledgeable of the concept of totality of evidence, which is a new data evaluation paradigm used to assess a One fundamental premise of biosimilars is that a product will be clinically evaluated in one or more indications of use, and the FDA may 'extrapolate' the totality of data to approve the biosimilar for use with other indications for which the originator biologic is approved. While only 12% of respondents surveyed are Fig. 2 Respondents were asked how long have biosimilars been available in the US. The correct answer is encircled Fig. 3 Respondents were asked what criteria they believe FDA will use to approve a biosimilar. There are three correct responses to this question: ' 'Data from at least one clinical study in a patient population that is sensitive to detect differences;' ' ' 'A comparison of PK/PD data for the biosimilar and its originator counterpart;' ' and ' 'A comparison of analytical characteristics between the biosimilar and its originator brand counterpart' ' comfortable with the concept of extrapolation ( Fig. S3 in Supplementary Materials), separate questions that assessed details of extrapolation reveal that most physicians are not familiar with the concept. This lack of knowledge was further highlighted at a US Advisory Committee meeting held on July 12-13, 2016, [13] whereby the panelists became more accepting of the concept after it was explained that extrapolation was based on totality of evidence data from the originator biologic molecule to the biosimilar molecule and not from the clinical aspects of one indication to another indication.
Almost 60% of respondents correctly understood that to be approved as ''interchangeable,'' a biosimilar must be shown to be safe and effective for back-and-forth switching with no negative impacts to safety or efficacy ( Fig. S4a in Supplementary  Materials) . However, there is a lack of awareness or misinformation about the term 'interchangeable' (Fig. S4b-e ).
Overall, one-third of respondents believe that the term means that approval of a biosimilar implies interchangeability with the originator biologic ( Fig. S4b) . In fact, an additional category was created within the US regulatory pathway for an interchangeable product. As of the time of writing of this article, the exact nature of the additional information that will be needed has not yet been defined, but is thought to include additional clinical data beyond that provided to establish biosimilarity. An overwhelming 80% of the respondents were not aware that interchangeability would enable a pharmacist to switch between originator biologic and biosimilar, and vice versa (Fig. S4c ).
Perceptions of Safety and Efficacy
More than half of respondents are aware that biosimilars must be comparable in safety and efficacy to the originator biologic, although that leaves a sizeable minority who are uncertain about these important approval criteria (Fig. 4 ). Physicians who are uncertain of this foundational fact are more likely to have reservations and may be cautious in adopting biosimilars. Nonetheless, a large percentage of respondents are unsure or concerned about Fig. 4 Respondents were asked which of the following statements are true when the FDA approves a biosimilar. Choices A and B are correct the safety of biosimilar medicines (Fig. 5 ), although the FDA can only approve a biosimilar if the agency is convinced that the safety profile is comparable to that of the originator biologic. This misconception could simply be due to a lack of knowledge, although the higher levels of uncertainty among rheumatologists compared to other specialties suggests that this concern may be caused, at least in part, by coordinated activities that raise questions about biosimilars and the biosimilar pathway, as biosimilars are being developed for several leading rheumatology products marketed in the US.
About half of respondents across all specialties specified that they wanted to have access to data directly evaluating the safety of switching patient populations from the originator biologic to its biosimilar (Fig. 6 ).
This highlights a potential concern of many physicians that the very act of switching may be dangerous because of concerns that the biosimilars may not be structurally identical to their reference product. It is likely that some physicians are unaware of two factors: (1) the primary sequence of a biosimilar must be identical to the reference product, and (2) that the quality attributes of all biologics (including both originator biologics and biosimilars) often vary from batch to batch within specified limitations, and that this variability has not led to safety concerns [14] . The critical quality attributes of batches of biosimilars must also be within the very same limits (pending FDA issuance of a guidance on statistical considerations for the analysis of analytic similarity). In addition, while not specified in the Biologics Price Competition Act of 2009 (BPCIA) [15] or in US guidance documents, as of September 2016, all biosimilar products approved by the FDA have incorporated at least one switch from originator biologic to biosimilar into their biosimilar clinical development programs. These important factors must be better communicated to physicians.
Fig. 5
Respondents were asked if they believe biosimilars will be safe and appropriate for use in naïve and existing patients More than one-third of respondents believe that abbreviated approval translates to a greater safety risk (Fig. 7) , which may reveal a basic misunderstanding that the ''abbreviated'' program refers to less supportive data. In fact, the analytical data requirement is much greater and forms the basis for the totality of evidence supporting biosimilarity. The ''abbreviated'' portion refers only to a requirement for fewer and smaller efficacy and safety studies because the purpose of biosimilar clinical studies is to confirm high similarity to the originator biologic and not to re-establish the safety and efficacy profile that was already established by the originator biologic.
Of the specialties, dermatologists and rheumatologists expressed significantly higher concerns at 43% and 48%, respectively.
Finally, the majority of physicians (85%) appreciate that, as is true for all biologics, the immunogenicity profile of a biosimilar will not be completely known pre-approval ( Fig. S5 in Supplementary Materials). To alleviate possible concerns about immunogenicity of a given biosimilar, it will be important to communicate the safety data that will be obtained from post-approval pharmacovigilance surveillance. It also may be useful to better communicate the safety data obtained with use of biosimilars in Europe, where there have been more than 400 million patient-days of experience in which no new immunogenicity concerns have been observed [5] .
Preferred Information Sources
Peer-reviewed literature is by far the most trusted and preferred information source for biosimilars among physicians (82%; Fig. S6 in Supplementary Materials). The top trusted Fig. 6 Respondents were asked if it would be essential for doctors to have data directly evaluating the safety of switching patients from an originator biologic to its biosimilar information sources include scientific journals (88%), FDA (73%), and physician peers (64%); however, dermatologists and rheumatologists indicated less trust in the FDA as an information source compared with other specialties at 64% and 58%, respectively ( Fig. S7 in Supplementary Materials). Physician trust in media was very low across all specialties (\5%). Journals, physician peers, and congresses/symposia are the primary trusted information sources for current information on biosimilars across specialties.
Physician Interests and Overall Thoughts
Approximately 60% of respondents are concerned about patient compliance with originator biologics and/or access to treatment options (Fig. 8) . A large majority of respondents believe that biosimilars will enable increased access and utilization, expand treatment options, and provide savings to the US healthcare system ( They would also like to see switching data.
When the FDA requires one-time switch data from originator biologic to biosimilar for chronic conditions, the switching data will be available but must be communicated. Fig. 7 Respondents were asked if they believe a biosimilar will be less safe than its originator biologic because it will be approved through an abbreviated pathway Fig. 8 Respondents were asked to rate their level of agreement with the following statement: ' 'With originator biologic medicines, I have concerns about my patients' compliance and/or access to treatment options' ' Fig. 9 Respondents were asked which biosimilars topics they were most interested in learning more about
Finally, most physicians are interested in learning more about key biosimilar concepts, suggesting an openness to learn. Topics of interest to physicians included product attributes of safety and efficacy and key concepts of biosimilars (totality of evidence, extrapolation, interchangeability), as well as information on access and the economics of biosimilars ( Fig. 9 ).
CONCLUSION
The results of this survey highlight a significant need for evidence-based education about biosimilars for physicians across specialties.
Although the vast majority of physicians have heard about biosimilars, their actual knowledge of the fundamentals of biosimilars was low, as the portion of respondents answering correctly rarely surpassed 50% for questions that focused on key aspects of these therapies. A similar survey will be repeated in 2-3 years time to monitor changes.
Biosimilar Definitions [16]
A BIOSIMILAR MEDICINE is a biologic that is highly similar to an FDA-approved biological medicine, known as an originator biologic. A biosimilar must be (1) highly similar to the originator biologic notwithstanding minor differences in clinically inactive components, and (2) have no clinically meaningful differences in safety or effectiveness compared to the originator biologic An INTERCHANGEABLE BIOLOGIC is a biosimilar that has been demonstrated to produce the same clinical result as its originator biologic in any given patient. In addition, for a product that is administered multiple times to an individual, the risk in terms of safety or diminished efficacy of alternating between use of the interchangeable biologic and its originator biologic is not greater than the risk of using the originator biologic alone. Designation of interchangeability requires additional supporting evidence, which will be further defined by the FDA An interchangeable biologic may be substituted by a pharmacist for the originator biologic or vice versa without the intervention of the healthcare professional who wrote the prescription. State laws govern the substitution process, and communication to the healthcare provider who wrote the prescription may be required after the product is dispensed EXTRAPOLATION is the process by which a biosimilar may be approved for one or more indications for which its reference biological product is licensed but for which there was no head-to-head clinical comparison. This approval is based on the extrapolation of the totality of data obtained with the biosimilar molecule in direct comparison to the originator biologic. Every indication for which extrapolation is sought must be scientifically justified
